TWI289450B - Anticancer agents - Google Patents
Anticancer agents Download PDFInfo
- Publication number
- TWI289450B TWI289450B TW089120410A TW89120410A TWI289450B TW I289450 B TWI289450 B TW I289450B TW 089120410 A TW089120410 A TW 089120410A TW 89120410 A TW89120410 A TW 89120410A TW I289450 B TWI289450 B TW I289450B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- cancer
- intellectual property
- cns
- ministry
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- -1 (4-Chlorophenyl)-tetrahydroxy-piperidinyl-2-propanol compound Chemical class 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 230000005907 cancer growth Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 43
- 150000001875 compounds Chemical class 0.000 abstract description 26
- 230000035755 proliferation Effects 0.000 abstract description 10
- 210000002950 fibroblast Anatomy 0.000 abstract description 9
- 239000007787 solid Substances 0.000 abstract description 7
- 230000002062 proliferating effect Effects 0.000 abstract description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract description 5
- 208000002260 Keloid Diseases 0.000 abstract description 4
- 206010023330 Keloid scar Diseases 0.000 abstract description 4
- 210000001117 keloid Anatomy 0.000 abstract description 4
- 230000003902 lesion Effects 0.000 abstract description 4
- 231100001231 less toxic Toxicity 0.000 abstract description 3
- 229940002612 prodrug Drugs 0.000 abstract description 3
- 239000000651 prodrug Substances 0.000 abstract description 3
- 150000008640 diphenylmethylpiperazines Chemical class 0.000 abstract description 2
- 230000003327 cancerostatic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 30
- 229940125904 compound 1 Drugs 0.000 description 26
- 201000011510 cancer Diseases 0.000 description 25
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229960004592 isopropanol Drugs 0.000 description 8
- 239000004593 Epoxy Substances 0.000 description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000002079 cooperative effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000009876 antimalignant effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940127084 other anti-cancer agent Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- NWVNXDKZIQLBNM-UHFFFAOYSA-N diphenylmethylpiperazine Chemical compound C1CNCCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NWVNXDKZIQLBNM-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000434 field desorption mass spectrometry Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- IANXAXNUNBAWBA-UHFFFAOYSA-N 2,2,3-trimethylundecane Chemical compound CCCCCCCCC(C)C(C)(C)C IANXAXNUNBAWBA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WFJFGMLKAISFOZ-UHFFFAOYSA-N 1-amino-3-iminourea Chemical compound NN=C(O)N=N WFJFGMLKAISFOZ-UHFFFAOYSA-N 0.000 description 1
- MZPZAIVRISPTJQ-UHFFFAOYSA-N 2,3,3a,4,5,6-hexahydro-1h-isoindole Chemical compound C1CCC2CNCC2=C1 MZPZAIVRISPTJQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- LZAYOZUFUAMFLD-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-hydroxypiperidine Chemical compound C=1C=C(Cl)C=CC=1C1(O)CCNCC1 LZAYOZUFUAMFLD-UHFFFAOYSA-N 0.000 description 1
- UBYXITFNZVIVDW-UHFFFAOYSA-N 4-methylbenzenecarboximidamide Chemical compound CC1=CC=C(C(N)=N)C=C1 UBYXITFNZVIVDW-UHFFFAOYSA-N 0.000 description 1
- QGFYFOHMBDMGBZ-UHFFFAOYSA-N 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol Chemical compound C1=C(O)C(CN(CC)CC)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 QGFYFOHMBDMGBZ-UHFFFAOYSA-N 0.000 description 1
- KSPDSMOWMQFPBL-UHFFFAOYSA-N 5-fluoropyrimidine Chemical compound FC1=CN=CN=C1 KSPDSMOWMQFPBL-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JJSRSMQEHCBYBR-UHFFFAOYSA-L C(C=1C(C(=O)[O-])=CC=CC1)(=O)OC.[Mg+2].COC(C=1C(C(=O)[O-])=CC=CC1)=O Chemical compound C(C=1C(C(=O)[O-])=CC=CC1)(=O)OC.[Mg+2].COC(C=1C(C(=O)[O-])=CC=CC1)=O JJSRSMQEHCBYBR-UHFFFAOYSA-L 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VANPZBANAIIRJW-UHFFFAOYSA-N diuranium Chemical compound [U]#[U] VANPZBANAIIRJW-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 description 1
- CMUOJBJRZUHRMU-UHFFFAOYSA-N nitrourea Chemical compound NC(=O)N[N+]([O-])=O CMUOJBJRZUHRMU-UHFFFAOYSA-N 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Description
經濟部智慧財產局員Η消費合阼汪印製 1289450 A7 ____B7_ 五、發明說明(1 ) 本發明係有關抑制癌生長之抗癌劑,亦即抗惡性腫瘤 劑,特別有關含有二苯甲基哌嗪衍生物,抑制含人體之哺 乳動物癌細胞生長之抗癌劑,亦即,抗惡性腫瘤劑者。又 ,本發明係有關爲了治療纖維芽細胞增殖後藉由做爲肺纖 維症疾病及抗癌劑副作用之纖維芽細胞增殖後其肺纖維症 疾病之增殖性病變的抑制纖維化劑者,特別是含有二苯甲 基哌嗪衍生物之爲了治療包括人類之哺乳動物增殖性病變 的抑制纖維化劑者。 先行技術中,做爲抗癌劑或抗惡性腫瘤劑之例者如① 梅爾法蘭、氮芥,及環磷醯胺等氮芥類、②B C N U、 C C N U、methyl- C CNU及ACNU等亞硝基尿素類、 ③三胺硫磷、絲裂霉素A Z Q、卡巴醌、夫二水半乳糖醇 及二溴衛茅醇等疊氮啉及環氧基類、④甲基苄肼、氮烯咪 胺以及六甲蜜胺等之烷化劑、⑤氮甲蝶呤(Μ 丁 X )、6 一硫基嘌呤(6 — Μ Ρ )、6 —硫代鳥嘌呤(6 - T G ) 以及 5 —氟脲嘧啶(5 — F U )、 tegafur( F 丁)、U F Τ 、5 D F U R及H C F U等5 -氟嘧啶及其類緣化合 物等代謝拮抗劑、⑤長春新驗、長春鹼及ν i n d e s i n e ( V D S )等長春花驗系化合物、etoposide及teniposide等 etoposide 系化合物、paclitaxel 及 Docetaxel 等之 taxan 類及 Jlhekan等等之喜樹鹼系化合物等之原於植物之抗癌劑、⑦ 阿霉素、cellvidin、更生霉素D、更生霉素、prenoxan、 絲裂霉素、間霉素及novanuone等抗癌性抗生物質、⑧ Adenocholticoid、雌激素、黃體素、抗雌激素、Alomatase !丨丨1!5_! (請先閱讀背面之注意事項再填寫本頁) 訂·- %丨 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -4- 1289450 A7 _____B7 五、發明說明(2 ) (請先閱讀背面之注意事項再填寫本頁) 阻礙劑、雄激素、抗雄激素及L Η — R Η類比物等激素劑 、⑨L 一天冬醯胺酶等酵素、⑩順氯胺鉑、羧氯胺鈾、及 nedaplatin ( 2 5 4 — S )等鉑絡合物、⑪非特異性免疫賦 活物質、⑫干擾素及⑬T N F類等者。 根據確立藉由此等抗癌劑之治療方法者,可使急性淋 巴性白血病、Hodgkin病等相當類度下回歸病患之社會生活 。惟’對於胃癌、肺癌及大腸癌等固形癌、大部份依賴外 科療法、及放射線治療者。對於此等固形癌,該順氯胺鉑 由於具有寬廣之抗腫瘤光譜,因此,順氯胺餡被用於固形 癌之治療使用。惟,順氯胺鉑被確定有腎毒性、胃腸毒性 、聽覺毒性及末梢神經毒性,且,治療率亦低等問題出現 〇 又,抗癌劑中倂發副作用之腺纖維症後,造成生命預 後之嚴重影響乃爲公知者。 本發明之目的在於解決此等抗癌劑之問題點者。 經濟部智慧財產局員工消費合阼f£印製 本發明係提供一種針對各種癌細胞具有極大抗癌活性 (亦即抗惡性腫瘤活性)或抑制肺纖維芽細胞增殖之性質 者,或,對於各種癌細胞可兼備極大抗癌活性(亦即抗惡 性壎瘤活性)及抑制肺纖維芽細胞增殖之性質者,毒性少 之化合物及其鹽以及其衍生物者爲目的。 本發明者發現一般式〔I〕 -5 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) [289450 A7 B7 五、發明說明( 3
⑴ 式中,R代表 〇〇. 或
C ------- 丨訂---------#to (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 者〕所不之化合物或其鹽及其衍生物或其前驅藥物不但毒 性比順氯胺鉑小,且比較順氯胺銷後,其對於各種癌細胞 具有極大抗癌作用,以及可抑制纖維芽細胞之增殖作用, 進而完成本發明。 亦即,本發明係以含有如一般式〔I〕所示之化合物 及其鹽’及其衍生物,或其前驅藥物者爲特徵之抗癌劑者 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -6- 1289450
R
經濟部智慧財產局員X-消費合itFi巾沒 A7 B7 五、發明說明(4 〔I〕 式中,R代表
或 C 1 者 〔圖面之簡單說明〕 圖1代表針對例2之該一般式〔I〕所示化合物等之 纖維芽細胞顯示抑制細胞增殖作用之曲線圖者。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
1289450 A7 __B7五、發明說明(5 ) 經濟部智慧財產局員工消費合作钍印製
〔發明之最佳實施形態〕 本發明中,一般式〔I〕
R ⑴ 〔式中,R代表
C I 者〕所示之化合物(以下,稱該一般式〔I〕所示之化合 物)或其鹽及其衍生物,或其前驅藥物(以下,綜合此等 ,稱該一般式〔I〕所示之化合物等)及其製造方法被揭 (請先閱讀背面之注意事項再填寫本頁)
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -8- 1289450 A7 B7 五、發明說明(6 ) 示於國際揭示號碼w〇 9 2 / 0 0 9 6 2號之國際揭示 公報及特開平4 - 6 9 3 7 7號公報(以下稱該公報等) 中。該公報等中,被揭示該一般式〔I〕所示之化合物等 未伴隨心抑制作用,抑制心肌過收縮及過舒展後,具有保 護因心肌壞死之作用者’以及具有治療及預防心肌梗塞之 效果,且,具有抑制心肌壞死及預防之效果者。 本發明者發現生體內(invivo)及生體外(in vitro ) 中,該一般式(I )所示之化合物比起順氯胺鉑及其其抗 癌劑其針對各種癌細胞具有良好之抗癌作用,對於各種癌 細胞顯示寬廣之抗癌光譜,同時發現該一般式〔I〕所示 之化合物等,具有抑制纖維芽細胞增殖之作用。 本發明中,抗癌劑之用語包括癌的治療劑及/或纖維 化抑制劑者。 本發明中,該一般式〔I〕所示化合物之「鹽」係指 醫藥學上可容許鹽之意,例如:鹽酸鹽、溴化氫酸鹽、硫 酸鹽、磷酸鹽或硝酸鹽等無機酸附加鹽;醋酸鹽、丙酸鹽 、琥珀酸鹽、二醇酸鹽、乳酸鹽、蘋果酸鹽、草酸鹽、酒 石酸鹽、檸檬酸鹽、馬來酸鹽、延胡索酸鹽、甲磺酸鹽、 苯磺酸酸、對-甲苯磺酸鹽或抗壞向酸鹽等有機酸附加鹽 ,或天冬胺酸鹽或谷胺酸鹽等胺基酸附加鹽,更含有含水 物及水和物,惟,並非僅限於此者。 本發明中,該一般式〔I〕所示之化合物「前驅藥物 」係指具有化學性或代謝性分解後取得之基者,藉由水解 ,加溶媒分解後,或於生理性條件下進行分解後,顯示做 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐〉 (請先閱讀背面之注意事項再填寫本頁) . 經濟部智慧財產局員工消費合作钍印製 -9- 1289450 A7 B7 五、發明說明(7 ) 爲抗癌劑之活性者,該一般式〔I〕所示化合物之衍生物 者。 本發明之該一般式〔I〕所示化合物等具有良好之抗 癌作用者。亦即,本發明抗癌劑係含有以該一般式〔I〕 所示化合物等做爲主藥者。本發明抗癌劑藉由倂用其他抗 癌劑投服後,則即使對於耐藥性之癌仍可發揮抗癌劑之制 癌作用。以本發明該一般式〔I〕所示化合物等做爲抗癌 劑使用時’一般可以全身性或局部性或以口服或非經口服 投用之。本發明之抗癌劑與其他抗癌劑同時投服亦可,或 先於其他抗癌劑投服之前,或投服之後投服均可。 投服量依其年齡、體重、症狀、治療效果、投服方法 及處理時間等而不同,一般成人(平均體重6 〇 k g ) — 人一天量爲0 · Olmg〜lg之範圍者,更佳者爲 100m g〜50〇mg之範圍者,1日1次或1日分爲 數次以口服或非經口投服之。以非經口投服時,可持續性 維持1 2小時投與之。 以本發明該一般式〔I〕所示化合物等做爲主藥調製 口服投用之固體組成物時,可爲錠劑、九劑、散劑、顆粒 劑等劑形。於此固體組成物中,可使1種或2種以上之主 藥混合1以上活性之稀釋劑、分散劑、或吸附劑等,例如 :乳糖、甘露糖醇、葡萄糖、羥丙基纖維素、微晶性纖維 素、澱粉、聚乙烯吡咯烷酮、甲基矽酸鋁酸鎂或無水矽酸 粉末等者。又,組成物亦可依常法混合稀釋劑以外之添加 劑。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
S . 經濟部智慧財產局員Η消費合作社印製 -10- 1289450 A7 B7 五、發明說明(8 ) (請先閱讀背面之注意事項再填寫本頁) 以本發明該一般式〔I〕所示化合物等做爲主藥調製 錠劑或九劑時,必要時,亦可以自糖、明膠、羥丙基纖維 素、或羥甲基纖維素苯二甲酸鹽等胃溶性或腸溶性物質之 薄膜進行被覆之,亦可被覆2層以上者。更可藉由明膠, 或乙基纖維素類之物質做成膠囊劑亦可。 以本發明一般式〔I〕所示化合物等做爲主藥進行調 製口服投用之液體組成物時,可爲藥劑上可容許之乳濁劑 ’溶解劑、懸浮劑、單糖劑或馳劑等劑形。此時,所使用 之稀釋劑如:精製水、乙醇、植物油或乳化劑等者。又, 此等組成物中除稀釋劑之外,亦可混合浸潤劑、懸浮劑、 甜味劑、風味劑、芳香劑、或防腐劑等補助劑類者。 以本發明該一般式〔I〕所示化合物等做爲主藥進行 調製非經口投用之注射劑時,可使用無菌水性或非水性溶 液劑、可溶化劑、懸浮劑或乳化劑。做爲水性溶液劑,可 溶化劑、懸浮劑者如:注射用水、注射用蒸餾水、生理食 鹽水、環糊精及其衍生物、三乙醇胺、二乙醇胺、單乙醇 胺、三乙胺等有機胺類或無機鹼溶液等。 經濟部智慧財產局員工消費合作社印製 本發明該一般式〔I〕所示化合物等做爲主藥進行做 成水溶性溶液劑時,亦可使用丙二醇、聚乙二醇、或橄欖 油類之植物油、或乙醇類之醇類等。又,做爲可溶化劑者 可使用聚環氧乙烷硬化篦麻子油,蔗糖脂肪酸酯等之界面 活性劑(混合膠粒之形成),或卵磷脂、氫化卵磷脂(核 糖核蛋白體形成)等者。亦可做成植物油等非水溶性溶解 劑與卵磷脂、聚環氧乙烷硬化箆麻油或聚環氧乙烷聚氧丙 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -11 - 1289450 A7 B7 五、發明說明(9 ) 二醇等所成之乳化製劑者。 (請先閱讀背面之注意事項再填寫本頁) 做爲非經口投用之其他組成物者可以含1種或2種以 上之主藥、亦即,該一航式〔I〕所示化合物藉由其本身 公知之方法做成外用液劑、軟膏類之塗佈劑、栓劑或陰道 栓劑等。 〔實施例〕 以下,針對以本發明該一般式〔I〕所示化合物等做 爲抗癌之主藥做成之製劑例進行具體的說明。惟,本發明 並非僅限定以下之說明者。 例1 本實施例抗癌劑注射製劑中,做爲主藥之例者,可使 用1 一〔 1 — 4 (二苯甲基)哌嗪基〕—3 —〔 1 —〔 4 一(4 一氯苯基)一 4 —羥基〕哌啶基〕一 2 —丙醇(以 下,稱化合物1 )。 經濟部智慧財產局員工消費合作社印製 針對該化合物1之合成例由以下進行說明。又,以下 說明中,核磁共振光譜(N M R )之測定係以四甲基矽烷 做爲內部標準進行後以p p m示之。份代表容量份。 (1) 1〜(二苯甲基)—4 一(1— (2 ,3 —環氧基 )丙基)暖嗦之合成 將1 0 · 0 g之1 —(二苯甲基)哌嗪溶於5 0 之 乙腈後,加入6 . 5 g之碳酸鈉及6 · 8 g之環氧溴丙院 -12- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1289450 A7 B7 五、發明說明(1Q) 之 後 , 進 行 加 熱 ί :® 流 2 ♦ 5 小 時 〇 將 臨濟 πτι. Va^、 別後, 使 濾液 進 行 減 壓 濃 縮 〇 以 矽 膠 柱 體 色 譜 法 ( W acogel C-200 丨, 200 g ) 進 行 毕主 m 製 殘 留 物 藉 由 9 9 份 氯 仿 與1 份甲醇 之 混合 溶 媒 進 行 溶 出 後 取 得 1 — ( 二 苯 甲 基 )- 4 一( 1 一( 2 3 一 環 氧 基 ) 丙 基 ) 哌 嗪 ( 5 • 9 g ) ο 核 磁 共 振 光 §並 口曰 1 · Η - -] Μ M R ( C i D ( 1 : 3、 5 〇 〇 MHz )5 : 2 • 3 〇 2 • 8 〇 ( 1 2 Η m ) j 3 • 〇 6 3 • 1 〇 ( 1 Η j m ) 4 • 2 3 ( 1 Η , S ) 5 7 • 1 6 ( 2 Η t > J = 7 • 3 Η z ) J 7 • 2 5 ( 4 Η 5 t J - 7 • 3 Η z ) J 7 4 0 ( 4 Η 5 d 5 J — 7 . 3 Η Z ) 0 (請先閱讀背面之注意事項再填寫本頁) i 經濟部智慧財產局員工消費合作社印製 (2) 1—〔1 — 4 —(二苯甲基)哌嗪基〕一 3 —〔 1 一〔4 — ( 4 —氯苯基)一 4 一羥基〕哌啶基〕一 2 -丙醇之合成 將3 ·〇g之1—(二苯甲基)一4 — (1— (2 , 3 —環氧基)丙基嗪及2 · 5 g之4 一( 4 一氯苯基 )一 4 一羥基哌啶溶於2 0 2之鄰一二氯苯中,進行加熱 還流2 . 5小時。放冷後,以砂膠柱體色層法(W a C 〇 - g e 1 C-200,1 00g )進行精製,取得 4 · 6 g 之 1 —〔 1 — 4 — (二苯甲基)哌啶基〕一 3 —〔 1 一 4 一(4 一氯苯基) 一 4 一羥基〕I啦啶基〕—2 —丙醇(化合物1 )者。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -13- 經濟部智慧財產局員X消費合阼il印製 1289450 A7 _ B7_ 五、發明說明(11 ) 紅外級收光譜:I R v m a X ( c m — 1 ) K B r : 33 〇〇,2950, 2650, 162 0, 145 0, 11〇〇,91〇,830,75〇,71〇(鹽酸鹽者 ) 核磁共振光譜 'H-NMR (CDC Is. 500MHz) ό: 1 · 5 0 〜1 · 9 〇(4 Η,m ), 2 ·〇 1 〜2 · 2 1 ( 2 Η ,m ), 2.30 〜2.55(1 〇H,m), 2.8〇〜2.9〇(2H,m), 3·87 〜3.93(lH,m), 4 · 2 2 ( 1 Η,s ), 7.16(2H,t,J=7.3Hz), 7.26(4H,t,J 二 7·3Ηζ), 7.3〇(2H,d,J = 8.5Hz), 7.40(4H,d,J=7.3Hz), 7.42(2H,d,J 二 8·5Ηζ)。 F D質譜 FD— MS (m/z) : 519,521(M+)。 (1 )化合物1的注射製劑 化合物1 2〜4〇m g D —山梨糖醇 1〇〇〇m g 檸檬酸 1 0 m g 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) —訂-------- •14- 1289450 Α7 Β7 五、發明說明(12) 氫氧化鈉 適量 注射用水 ..注射用水加入做成2 0 · 0 2者。 (請先閱讀背面之注意事項再填寫本頁) 將D -山梨糖醇及檸檬酸溶於充份量之注射用水。使 化合物1溶解於所取得之溶液後,以氫氧化鈉調節P Η爲 3 · 2〜3 · 3。再於攪拌同時加入殘量注射用水。過濾 此溶液後塞入2 0 . 0 2安瓶中進行密封。此安瓶內容物 以高壓鍋進行滅菌。 (2 )各種人體癌細胞株中,針對invhro抗腫瘤效果藉由 Μ T T試驗法進行檢討。 經齊郎fe>曰慧时轰笱員1-肖費^乍:±1巾:^ 分別將人體非小細胞肺臟癌細胞株P C - 1 4、人體 小細胞肺臟癌細胞株S B C - 3、人體乳癌細胞株M C F 一 7、人體卵巢癌細胞株S Κ〇V 3、人體白血病細胞 株H L 6 0及人體大腸癌細胞株W i D R於R Ρ Μ I 1 6 4 0培養基中利用胰蛋白酶處理或細胞刮板做成單細 胞,調製1 5 μ 1爲1 0 0個細胞浮遊液。此做爲抗癌劑 化合物1者溶於二甲亞砸後,使化合物1之濃度加至 〇· 5〜1 // m之範圍,將此於9 6孔之感光板爲1焊接 各以1 5 0 μ 1置入。此感光板於3 7 °C之溫度下,5 % 二氧化碳濃度及飽和水蒸氣之條件下,維持9 6小時,進 行培養之。培養後,於D — P B S (—)中加入2 0 // 1 之於5 m g / m 1濃度所溶解之Μ T T〔 3 -( 4,5 — 二甲基噻唑一 2 -基)一 2,5 —二苯基四唑嗡溴化物( 3— (4,5 —二甲基噻唑一 2 —烯基)一2,5 —二苯 -15- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1289450 A7 B7 五、發明說明(13 ) 基四唑嗡溴化物)〕試藥,更於3 7 °C下進行培養4小時 。培養結束後,各感光板進行離心分離後,丟棄上淸液。 加入2 0 0 // 1之二甲亞砸後,使黃色之Μ T T藉由癌細 胞內線粒體之脫氫酵素作用所產生之紫色甲臢溶解後,將 所生成之甲腊之量藉由多感光板讀取器測定針對波長 5 6 2〜6 3 0 n m之吸光度。陰性對照之平均發育率做 爲0 %,陽性對照之平均發育率做爲1 0 0 %後,描出腫 瘤容量發育曲線後,算出化合物1 ,5 0 %之抑制人體癌 細胞增殖之濃度。結果如表1所示。 表 1 細胞株 達成I C 5。所需化合 物1之量(// Μ ) P C - 1 4 (人體非小細胞肺癌株) 1 . 0 2 ± 0 . 2 0 S B C - 3 (人體小細胞肺癌株) 〇.4 6 土 0 · 0 3 M C F - 7 (人體乳癌株) 0 . 6 0 ± 0 . 0 8 SKOV3 (人體卵巢癌株) 〇· 8 5 ± 0 · 0 2 HL — 6 0 (人體白血病株) 1 · 1 8 ± 0 ·〇 5 Wi DR (人體大腸癌株) 〇 . 4 1 ± 0 · 0 3 表1之値係於3次獨立使用化合物1之癌細胞培養實 驗中Μ T T試驗5 0 %抑制癌細胞增値之濃度(I C 5 〇 ) 値以平均値土誤差範圍(μ Μ )代表之。 如表1所示,化合物1於0 · 5〜1 · 1 μ Μ之濃度 -!!·#! (請先閱讀背面之注意事項再填寫本頁) . 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -16- 經濟部智慧財產咼員1.消費^阼比中:^ 1289450 A7 _____ B7__ 五、發明說明(14 ) 下,針對各種癌細胞所顯示5 0 %抑制增殖之效果(I C 5 〇 )者。針對此化合物1之I C 5 〇値比起對於固形癌最有 效之順氯胺鈾中Μ T T測試法後I c 5 〇値之2〜3 μ Μ, 其値爲極低,由化合物1之I C 5。値可證明化合物1之制 癌效果極大,可有效做爲抗癌劑者。另外,對於肺臟癌、 乳癌、大腸癌、卵巢癌等固形癌細胞亦與對於白血病細胞 之抗腫瘤效果顯現同等之程度爲具有寬廣抗腫瘤光譜者。 例2 對照,分別於化合物1濃度爲1 X 1 0 — 6 Μ之系列及 化合物1濃度爲3 X 1 0 6 Μ之系列中準備9片培養皿( 合計2 7片)。於2 7片培養皿中分別加入每培養皿爲 4 · 4 X 1 0 5個之纖維芽細胞Ν I Η 3 Τ 3,分別加入含 1 0 % F B S (牛胎血淸)之D — Μ Ε Μ培養液。對照以 加入相當化合物1添加量之水進行培養之。每2 4小時進 行測定各系列3片細胞數,算取平均後,做成每培養皿之 平均細胞數,其結果如圖1所示。如結果所示,化合物1 具有抗癌作用之同時,對於藉由纖維芽細胞之增殖後,造 成的間質性肺炎、瘢痕瘤等增殖性病變亦有效。 例3 於雌性無毛實驗鼠B A L B / c n u / n u ( 6週 齡)中,以2 x 1 0 7個人體非小細胞肺藏癌株p c — 1 4 之細胞做爲生理食鹽水浮遊攸’植入背邰皮下後’觀察其 (請先閱讀背面之注意事項再填寫本頁) · 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -17- 1289450 A7
7 R 五、發明說明(16 ) 做爲第1天腫瘤容積之大小示之。 經濟部智慧財產局員工消費合作社印製 表 2 系 列 號 碼 被 檢 體 號 碼 第 1 曰 第 2 曰 第 3 曰 第 4 曰 第 5 曰 第 6 曰 第 7 曰 第 8 曰 1 1 100.00 111.45 148.16 179.50 233.01 208.06 230.37 290.31 1 2 100.00 145.96 116.07 117.73 107.15 61.17 108.09 131.77 1 3 100.00 103.15 71.62 72.94 74.51 55.21 72.46 60.61 1 4 100.00 169.32 143.35 149.41 205.18 214.09 221.72 265.04 1 5 100.00 91.66 140.09 114.08 111.79 188.97 165.66 182.55 1 6 100.00 131.69 147.32 85.63 132.46 87.52 113.77 127.27 2 1 100.00 45.35 20.22 46.17 31.44 30.93 52.68 56.49 2 2 100.00 120.51 98.14 80.18 68.58 122.90 99.04 127.45 2 3 100.00 139.67 85.27 105.01 67.76 55.16 75.58 130.56 2 4 100.00 73.21 52.91 42.19 22.55 0.00 0.00 0.00 2 5 100.00 73.29 62.47 31.02 18.55 10.11 12.98 4.97 2 6 100.00 66.68 83.06 85.73 51.09 51.30 47.68 30.49 3 1 100.00 55.40 58.27 79.34 47.44 33.96 34.07 47.99 3 2 100.00 63.47 43.51 40.73 40.65 32.21 36.27 15.80 3 3 100.00 93.53 72.22 83.65 62.95 54.93 86.76 102.87 3 4 100.00 68.25 113.73 123.79 103.32 135.18 129.59 140.33 3 5 100.00 90.42 70.23 36.86 28.95 14.65 17.36 7.22 3 6 100.00 80.68 92.68 84.55 79.20 51.96 85.12 61.54 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -19- 1289450 A7 B7 五、發明說明(17) 表_3 系 列 號 碼 平均 (6隻) 第 1 曰 第 2 曰 第 3 曰 第 4 曰 第 5 曰 第 6 曰 第 7 曰 第 8 曰 1 100.00 121.23 124.35 121.20 147.83 143.83 159.88 165.10 2 100.00 89.79 67.01 68.38 46.68 47.73 42.99 58.33 3 100.00 78.63 75.11 74.99 60.45 53,82 64.86 62.63 (請先閱讀背面之注意事項再填寫本頁) 1—〔 1 一 4 一(二苯甲基)哌嗪基〕一3 —〔 1 一〔 4 一(4 —氯苯基)—4 一羥基〕哌啶基〕一 2 -丙醇 由例1至例3結果證明化合物1具極大制癌效果。 該例1至例3中,以化合物1之1 一〔一 4 —(二苯 甲基)_嗪基〕—3 —〔 1 一〔 4 — ( 4 一氯苯基)一 4 一羥基〕_啶基〕一 2 —丙醇做爲主藥使用,而以1 —〔 2 — ( 1 ,2,3,4 —四氫)異喧啉基〕—3 —〔 1 — (4 一二苯甲基)哌嗪基〕一 2 -丙醇做爲主藥使用亦可 ,其結果相同。 經濟部智慧財產局員工消費合作社印製 針對1 —〔 2 -( 1 ,2,3,4 一四氫)異D奎啉基 〕一 3 —〔 1 一(4 一二苯甲基)哌嗪基〕—2 —丙醇之 合成例’於以下進行說明之。又,以下說明中,核磁氣共 振光譜(N M R )之測定係以四甲基矽烷做爲內部標準進 ί了後’以P p m代表之。份代表容纛份。 (1) 2 —〔1— (2,3 —環氧基)丙基〕—1 ,2, 3 ,4 一四氫異咱啉之合成 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -20- 經濟部智慧財產局員工消費合作社印製 1289450 A7 ____B7_ 五、發明說明(18 ) 將2 5 · 0 g之1 ,2 ,3 ,4 —四氫異喹啉溶於 1〇0 2乙腈後,於此加入4 0 . 0 g之碳酸鈉及 3 1 . 0 g之環氧溴丙烷進行4小時加熱還流。將濾別鹽 後之濾液進行減壓濃縮。以矽膠柱體色譜法(Waco gel-200 、500 g )精製殘留物,藉由9 9份氯仿與1份之甲醇混 合溶媒進行溶出後,取得1 5 · 6 g之2 -〔 1 一( 2, 3 —環氧基)丙基〕—1 ,2 ,3 ,4 一四氫異喹啉。 核磁共振光譜 'H-NMR (CDC Is. 1 0 0 Μ Η z ) 5 : 2.36 〜2.6〇(2H,m), 2.73 〜3.〇3(6H,m), 3.〇9〜3.29(lH,m), 3.65 (lH,d,J = 14.9Hz), 3 · 8 3 ( 1 H,d, 例4 將3 ·〇g之2 — 〔1— (2 ,3 —環氧基)丙基〕 —1 ,2 ,3 ,4 —四氫異喹啉及4 · 4g之1—(二苯 甲基)哌嗪溶於2 0 2之鄰一二氯苯後,進行2 . 5小時 加熱還流。放冷後,以矽膠柱體色譜法(Waco gel C-200 、150 g )進行精製後,取得6 . 0 g之1 —〔 2 — ( 1 ,2 ,3 ,4 —四氫)異喹啉基〕一 3 —〔 1 一( 4 一二 苯甲基)呢嗦基〕一 2 -丙醇。 紅外吸收光譜:I R m a X ( c m — 1 ) K B r : 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
-21 - 經濟部智慧財產局員Η消費合阼Fi印製 1289450 A7 ___B7_ 五、發明說明(19 ) 340〇,3〇〇〇,255〇,162 0, 145 0, 10 80 ,92〇,760 ,71〇(鹽酸鹽者) 核磁共振光譜 1 Η - N M R ( C D C la, 1 〇 0 Μ H z ) 5 : 2.3 0 〜2.60(1.2H,m), 2.75 〜2.95(4H,m), 3.62 〜3.8〇(2H,m), 3.92 〜4.03(lH,m), 4 · 2 1 ( 1 H,s ), 7.〇〇〜7.51(14H,m)。 F D質譜 FD— MS (m/z) :441 (M+)。 (2) 1—〔2 — (1 ,2,3 ,4 一四氫)異喹啉基〕 一 3 —〔 1 — ( 4 —二苯甲基)哌嗪基〕-2 —丙 醇之合成 將3 ·〇g之2 —〔1— (2 ,3 —環氧基)丙基〕 —1 ,2,3 ,4 —四氫異d奎啉及4 . 4g之1 一(二苯 甲基)|帳嗪溶於2 0 2之鄰一二氯苯中後,進行2 · 5小 時加熱還流。放冷後,以矽膠柱體色譜法(Waco gel C-200 、15 0 g )進行精製後,取得6 . 0 g之1 —〔 2 — ( 1 ’ 2,3,4 —四氫)異d奎啉基〕—3 —〔1_ (4 一二苯 甲基)哌嗪基〕一 2 -丙醇化合物。 紅外吸收光譜:I R v max (cm1) K B r · 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
-22 - 1289450 A7 B7 五、發明說明(20) 34〇〇,3〇〇〇,255〇,1620’ 1450’ 1〇8〇,92〇,76 0 ,71〇(鹽酸鹽者) (請先閱讀背面之注意事項再填寫本頁) 核磁共振光譜 'H-NMR (CDC l3> 1 0 0 Μ Η z ) ά : 2 · 3 0 〜2 · 6 0 ( 1 · 2 Η,m ), 2·75 〜2·95(4Η,ιώ) ’ 3.62 〜3.8〇(2H,m), 3.92 〜4.03(lH,m), 4 · 2 1 ( 1 Η,s ), 7·〇〇〜7·51 (l4H,m)。 F D質譜 FD— MS (m/z) : 441 (M+)。 〔產業上可利用性〕 經濟部智慧財產局員工消費合作社印製 本發明該一般式〔I〕所示化合物等比先行之抗癌劑 如:順氯胺鈾之毒性較小,且比先行抗癌劑對於各種癌細 胞更具極大制癌作用、顯示寬廣制癌光譜、比起先行抗癌 劑其癌(固形癌)及其他惡性腫瘤等之癌治療上更具極大 貢獻者。又,本發明具有抑制肺纖維症等之纖維芽細胞之 增殖作用,比起先行之肺纖維症、瘢痕瘤等治療藥後’更 具良好之纖維化抑制作用,於肺纖維症、瘢痕瘤治療上更 具極大貢獻者。 -23- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 第89120410號專利申請案 中文說明書修正頁 1289450 民國95年11月15日修正 申請曰期 89 年 9 月 30 曰 案 號 89120410 類 別 論編,麵4 (·以上i欄去本局填註f 1 公4
4H C4 I 95. 11. 15 中 文 抗癌劑 發明 新型 名稱 英 文
Anticancer agents 姓 名 國 籍 (1) 金子舁 (2) 西尾和人 (1)日本 0 日本 裝 發明 創作' (1)日本國東京都文京區春日二丁目二三番一二一 四〇三號 住、居所 0 §本國千葉縣印西市西©原一一二一四一三〇 訂 姓 名 (名稱) (1)金子昇 金子舁 _ 線 經濟部智慧財產均員工消費合作社印製 申請人 國 籍 住、居所 (事務所) 代表人 姓 名 (1)日本 (1)日本國東京都文京區春日二丁目二三番一: 四〇三號 本紙張尺度適用中國國家標準(CNS ) A4規格(210X:Z97公釐) 128945沪89120410號專利申請案 中文說明書修正頁 民鼸95年11月15日修正 B7 五、發明説明(彳5) 生存經過。選出移植後第7天腫癌狀態所確定後可試驗之 個體,進行各個體之抽樣,分別以6隻分成對照系列,第 1被檢系列及第2被檢系列。將各被移植腫瘤之腫瘤容積 進行測定腫瘤之短徑及腫瘤之長徑後,藉由腫瘤短徑之平 方與腫瘤長徑之積,亦即,式:(腫瘤短徑)2 X (腫瘤長 徑)進行求取之。腫瘤移植後,由第7天開始投用化合物 1 ° 將1.2mg化合物1溶於〇.〇 5J之二甲亞硕後,加 入0 · 9 5W之0 · 5%山梨糖醇一 0.2%檸檬酸1水和 物溶液(P Η 3 . 3 )使成均勻溶液後,做成化合物1注射液 〇 化合物1之投用係6隻系列號碼3之被檢體群中,於 腫瘤移植後第7天、第8天、第9天、第10天及第 1 1天分別由無毛實驗鼠尾處以1日1次注射1 kg體重爲 5 mg之化合物1。做爲對照系列號碼1之被檢體群爲未投 用化合物1之系列者,完全未投用化合物1及治療者。針 對整體被檢體群由第1天化合物1投用至第8天於每日一 次投用化合物1前者,及針對每日一次,觀察各實驗鼠之 全身狀態及各老鼠體重及腫瘤容積進行測定。其實驗鼠全 身狀態之觀察及體重所測定之結果系列號碼1至3之被檢 體群間幾乎未有差異,而實驗鼠腫瘤容積其系列號碼1至 3之被檢體群間卻出現差異。腫瘤容積測定結果如表2所 示,其每系列號碼之被檢體群腫瘤容積平均値如表3所示 。表2及表3中,第2天以後腫瘤容積之大小係以1 0 〇 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) I — I!----0! (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局g(工消費合作社印製 -18-
Claims (1)
1289450 ,., 1· \ Α8 I.丨 Β8 ::J C8 ! D8 、申請專利範圍 第8 9 1 2 04 1 0號專利申請案 中文申請專利範圍修正本 民國95年11月15日修正 1 . 一種使用於抑制癌細胞成長的醫藥組合物,其 特徵係含有如一般式〔I〕所示1 — 〔 1 — 4 一 (二苯 甲基)_嗪基〕—3 — 〔1 一 〔4 一 (4 —氯苯基)一 4 一羥基〕哌啶基〕-2 -丙醇之化合物及其鹽
⑴ 〔式中,R代表
經濟部智慧財產局員工消費合作社印製 或
(請先閲·«背面之注意事項再填寫本頁)
本紙張尺度適用中國國家樣準(CNS ) Α4規格(210 X 297公釐) 1289450 A8 B8 C8 D8 六、申請專利範圍 者
C I (請先閲嘩背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28087499 | 1999-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI289450B true TWI289450B (en) | 2007-11-11 |
Family
ID=17631164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW089120410A TWI289450B (en) | 1999-09-30 | 2000-09-30 | Anticancer agents |
Country Status (8)
Country | Link |
---|---|
US (1) | US6683083B1 (zh) |
EP (2) | EP1222924B1 (zh) |
AT (2) | ATE349212T1 (zh) |
AU (1) | AU776745B2 (zh) |
CA (1) | CA2385996C (zh) |
DE (2) | DE60034494T2 (zh) |
TW (1) | TWI289450B (zh) |
WO (1) | WO2001022968A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
EP1603450A4 (en) | 2003-03-07 | 2009-07-29 | Univ Columbia | METHODS USING TYPE 1 RYANODINE RECEPTOR |
US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20070052304A1 (en) * | 2005-09-07 | 2007-03-08 | Philippe Masson | Multi-pattern high temperature superconducting motor using flux trapping and concentration |
JP5318938B2 (ja) * | 2011-06-09 | 2013-10-16 | 株式会社アエタスファルマ | ジフェニルメチルピペラジン誘導体、及びそれを用いた医薬組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
JP2651043B2 (ja) | 1990-07-10 | 1997-09-10 | 麒麟麦酒株式会社 | ジフェニルメチルピペラジン誘導体 |
JP2518965B2 (ja) * | 1990-09-21 | 1996-07-31 | 三井東圧化学株式会社 | 新規ピリジン誘導体及びそれを有効成分として含有する制癌剤効果増強剤 |
-
2000
- 2000-09-29 US US10/089,718 patent/US6683083B1/en not_active Expired - Fee Related
- 2000-09-29 EP EP00962991A patent/EP1222924B1/en not_active Expired - Lifetime
- 2000-09-29 CA CA002385996A patent/CA2385996C/en not_active Expired - Fee Related
- 2000-09-29 WO PCT/JP2000/006786 patent/WO2001022968A1/ja active IP Right Grant
- 2000-09-29 AU AU74498/00A patent/AU776745B2/en not_active Ceased
- 2000-09-29 DE DE60034494T patent/DE60034494T2/de not_active Expired - Lifetime
- 2000-09-29 DE DE60032620T patent/DE60032620T2/de not_active Expired - Lifetime
- 2000-09-29 AT AT00962991T patent/ATE349212T1/de active
- 2000-09-29 AT AT05077245T patent/ATE359788T1/de active
- 2000-09-29 EP EP05077245A patent/EP1637140B1/en not_active Expired - Lifetime
- 2000-09-30 TW TW089120410A patent/TWI289450B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1222924A1 (en) | 2002-07-17 |
EP1222924A4 (en) | 2004-08-04 |
EP1637140A1 (en) | 2006-03-22 |
EP1637140B1 (en) | 2007-04-18 |
CA2385996C (en) | 2008-02-12 |
ATE359788T1 (de) | 2007-05-15 |
DE60032620T2 (de) | 2007-10-04 |
US6683083B1 (en) | 2004-01-27 |
DE60034494D1 (de) | 2007-05-31 |
DE60034494T2 (de) | 2008-01-03 |
WO2001022968A1 (fr) | 2001-04-05 |
AU776745B2 (en) | 2004-09-23 |
CA2385996A1 (en) | 2001-04-05 |
EP1222924B1 (en) | 2006-12-27 |
ATE349212T1 (de) | 2007-01-15 |
AU7449800A (en) | 2001-04-30 |
DE60032620D1 (de) | 2007-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI289450B (en) | Anticancer agents | |
US10793543B2 (en) | Selective C-KIT kinase inhibitor | |
KR101677790B1 (ko) | 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제 | |
KR101668931B1 (ko) | 항종양제의 효과 증강제 | |
KR101762999B1 (ko) | 종양 치료제 | |
WO2006080327A1 (ja) | α,α,α-トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 | |
AU2016272057A1 (en) | Use of pteridinone derivative serving as EGFR inhibitor | |
EP3176160B1 (en) | Pyridine-substituted 2-aminopyridine protein kinase inhibitors | |
ES2385850T3 (es) | Potenciador de radioterapia | |
CN107245075A (zh) | 2,4,6‑三取代吡啶并[3,4‑d]嘧啶类化合物及其盐和应用 | |
CN104876928B (zh) | 7-氮杂吲哚啉-2-酮类化合物及其制备方法 | |
EP3418271A1 (en) | Novel indole derivative and anti-cancer composition containing same | |
CN103936762B (zh) | 吗啉并喹啉类化合物,其制备方法和用途 | |
CN103965175B (zh) | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 | |
CN107141284A (zh) | 黄连碱类衍生物、其制备方法、药物组合物及抗肿瘤用途 | |
EA032865B1 (ru) | НОВАЯ КРИСТАЛЛИЧЕСКАЯ СОЛЕВАЯ ФОРМА 3-(1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИН-3-ИЛЭТИНИЛ)-4-МЕТИЛ-N-(4-((4-МЕТИЛПИПЕРАЗИН-1-ИЛ)МЕТИЛ)-3-ТРИФТОРМЕТИЛФЕНИЛ)БЕНЗАМИДА ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ | |
JP4152576B2 (ja) | 抗がん剤 | |
CN108774220B (zh) | 用于治疗心肌缺血的化合物及其应用 | |
CN105130960A (zh) | 1,3,5-三嗪类衍生物及其应用 | |
CN109575044A (zh) | 2-(喜树碱-10-氧基)乙酰胺类化合物和应用 | |
CN103998428B (zh) | 二苯基甲基哌嗪衍生物及使用该衍生物的医药组合物 | |
CN107365280A (zh) | N-(噻唑-2-基)哌嗪基酰胺衍生物及其作为抗癌药物的应用 | |
CN106995368B (zh) | 一种非atp竞争性fgfr1抑制剂及其应用 | |
CN107011337A (zh) | N‑[5‑(1,2,4‑三唑‑1‑基)噻唑‑2‑基]哌啶基酰胺及其医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |